21-Dec-2021
Mail & Guardian
If the states of the world take seriously their own rhetorical commitments to climate change mitigation, job creation, and sustainable development, they must reject the free trade paradigm.
20-Dec-2021
Business Standard
Intellectual Property protection and enforcement, standards, tariffs on several products, and data protection are among the key issues that would dominate the India-UK FTA.
13-Dec-2021
Afronomics Law
African nations should not be expected to take the lead in addressing a climate emergency they did not create. The priority for Africa is to receive support and investment to build resilience and adapt to climate impacts.
22-Nov-2021
South China Morning Post
As the two-year deadline for the phase-one trade deal between the world’s two largest economies is approaching, all eyes are on the next step.
17-Nov-2021
The Independent
There is evidence of a potential conflict between the CPTPP and the UK’s current system of market authorisation of generic and biosimilar drugs.
21-Oct-2021
European Commission
4-Oct-2021
The Hindu Businessline
On a tight time schedule for the proposed India-UAE free trade pact, the DPIIT has called for suggestions from industry bodies and other stakeholders on IPR issues that could make it easier for Indians to do business in the UAE.
20-Sep-2021
Socialist Project
Transnational companies today rely more than ever on IPR to structure their global value chains, writes Peter Rossman
2-Sep-2021
Vanguard News Nigeria
AfCFTA roundtable brought together business leaders, academia, government representatives, trade, and legal experts to discuss and deliberate on dispute issues in implementing the agreement in Nigeria.
27-Jul-2021
The Hindu Businessline
India and the EU are likely to begin negotiations on the revamped proposal for a bilateral FTA in September but there continues to be disagreement on whether to carve out separate agreements on investment protection and geographical indications (GIs).
14-Jul-2021
Globalization and Health
This paper examines civil society and health actors’ views of the conditions that successfully contributed to the removal of these measures in RCEP, with a focus on intellectual property and access to medicines.